- Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall response rate (ORR), 11.1 months median duration of response, and a generally well-tolerated safety profile
- EphA2-targeting BT5528 demonstrated an emerging differentiated safety profile and antitumor activity in patients with advanced solid tumors, including a 45% ORR in mUC 6.5 mg/m2 every two weeks-dose expansion cohort
- Relatively low frequency and severity of treatment-related peripheral neuropathy following monotherapy with Bicycle Toxin Conjugates zelenectide pevedotin and BT5528, with patients often able to continue therapy without modification
- BT7480 demonstrated a favorable safety profile and preliminary antitumor activity in advanced Nectin-4-associated solid tumors
Reported Saturday, Bicycle Therapeutics Announced Updated Phase 1/2 Results For Zelenectide Pevedotin (Formerly BT8009) In Metastatic Urothelial Cancer, BT5528 In Advanced Solid Tumors And BT7480 In Advanced Solid Tumors
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated